A single family office is an active investor in early-stage companies. The firm is very flexible in terms of investment size they are generally looking to invest a minimum of $.5 million per round, depending upon size of round and estimated capital call. The firm prefers A round and later stage companies. Pre-A interest depends upon technology stage. Currently, the firm is investing only in companies based in North America.
The firm is looking for breakthrough technologies with a strong social ethos in the Therapeutics, Medical Devices, and Diagnostics Sectors that address underserved medical needs or provide innovative and disruptive approaches to common medical procedures and treatments. Currently, of particular interest are optical or sound-based technologies, devices that supplant drug use, orthopedics, gene/nucleic acid-based therapies, immuno-oncology and therapies correcting or treating loss of senses.
The firm is currently reviewing co-investment opportunities in private companies and on an opportunistic basis, considering investment in micro-and small-cap public companies as a direct investor. The firm is looking for companies that have already raised seed financing and have received allowance of claims by the USPTO.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment